HAVCR2 and cancer: Inhibition of stemness‐related pathways has been reported not only to reduce the tumorigenic activity of cancer stem cells but also to impair expression of multiple immune checkpoints on cancer stem cells, including PD‐L1, TIM3, and CD24.40